<SEC-DOCUMENT>0001558370-19-011325.txt : 20191204
<SEC-HEADER>0001558370-19-011325.hdr.sgml : 20191204
<ACCEPTANCE-DATETIME>20191204160100
ACCESSION NUMBER:		0001558370-19-011325
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20191203
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191204
DATE AS OF CHANGE:		20191204

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Precipio, Inc.
		CENTRAL INDEX KEY:			0001043961
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				911789357
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36439
		FILM NUMBER:		191268188

	BUSINESS ADDRESS:	
		STREET 1:		12325 EMMET ST
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164
		BUSINESS PHONE:		203 787 7888

	MAIL ADDRESS:	
		STREET 1:		4 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRANSGENOMIC INC
		DATE OF NAME CHANGE:	20000119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8-k.htm
<DESCRIPTION>8-K
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.4.0.81-->
<!--Created on: 12/4/2019 2:00:49 PM-->
<html>
	<head>
		<title>
			PRPO - 8K - Resignation and Appointment of Director Dec 3 2019
		</title>
	</head>
	<body><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<div><hr style="border-width:0;width:100%;height:1.5pt;color:gray;background-color:gray;" align="center"></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">UNITED STATES</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION<br></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">WASHINGTON, D. C. 20549</font>
		</p>
		<div><hr style="border-width:0;width:20.59%;height:1.5pt;color:gray;background-color:gray;" align="center"></div>
		<p style="margin:0pt 0pt 6pt;text-align:center;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;">FORM 8-K </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;">CURRENT REPORT<br>PURSUANT TO SECTION 13 OR 15(d) OF THE<br>SECURITIES EXCHANGE ACT OF 1934 </font>
		</p>
		<p style="margin:5pt 0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Date of Report (Date of earliest event reported): December 3, 2019</font>
		</p>
		<p style="margin:5pt 0pt;text-align:center;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;">PRECIPIO, INC.<br></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">(Exact name of registrant as specified in its charter)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:128.60pt;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:11.80pt;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:132.20pt;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:11.80pt;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:158.40pt;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:128.60pt;padding:0pt 6.5pt">
					<p style="margin:5pt 0pt;line-height:115%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;">Delaware<br></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">(State or other jurisdiction of incorporation)</font></p>
				</td>
				<td valign="top" style="width:11.80pt;padding:0pt 6.5pt">
					<p style="margin:5pt 0pt;line-height:115%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:132.20pt;padding:0pt 6.5pt">
					<p style="margin:5pt 0pt;line-height:115%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:10pt;">001-36439<br></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">(Commission File Number)</font></p>
				</td>
				<td valign="top" style="width:11.80pt;padding:0pt 6.5pt">
					<p style="margin:5pt 0pt;line-height:115%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:158.40pt;padding:0pt 6.5pt">
					<p style="margin:5pt 0pt;line-height:115%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:10pt;">91-1789357<br></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">(IRS Employer Identification No.)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">4 Science Park, New Haven, CT 06511</font>
		</p>
		<p style="margin:5pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(Address of principal executive offices) (Zip Code)</font>
		</p>
		<p style="margin:0pt 0pt 5pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> (203) 787-7888</font>
		</p>
		<p style="margin:5pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(Registrant's telephone number, including area code)</font>
		</p>
		<a name="page_de1292_1_2"></a><div><hr style="border-width:0;width:20.59%;height:1.5pt;color:gray;background-color:gray;" align="center"></div>
		<p style="margin:0pt 0pt 5pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">Not Applicable<br></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;">(Former name, former address and former fiscal year, if changed since last report date)</font>
		</p>
		<div><hr style="border-width:0;width:20.59%;height:1.5pt;color:gray;background-color:gray;" align="center"></div>
		<p style="margin:0pt 0pt 6pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </font>
		</p>
		<p style="margin:0pt 0pt 6pt 18pt;text-indent: -18pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&#x2610;<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;font-family:Wingdings;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </font>
		</p>
		<p style="margin:0pt 0pt 6pt 18pt;text-indent: -18pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&#x2610;<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;font-family:Wingdings;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </font>
		</p>
		<p style="margin:0pt 0pt 6pt 18pt;text-indent: -18pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&#x2610;<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;font-family:Wingdings;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </font>
		</p>
		<p style="margin:0pt 0pt 6pt 18pt;text-indent: -18pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&#x2610;<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;font-family:Wingdings;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:33.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;height:5.50pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:5.50pt;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:34.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;height:5.50pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:5.50pt;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:33.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;height:5.50pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:5.50pt;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:560.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Securities registered pursuant to Section 12(b) of the Act:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:33.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;height:19.64pt">
					<p style="margin:0pt;line-height:115%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Title of each class</font></p>
				</td>
				<td valign="bottom" style="width:34.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;height:19.64pt">
					<p style="margin:0pt;line-height:115%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Ticker symbol(s)</font></p>
				</td>
				<td valign="bottom" style="width:33.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;height:19.64pt">
					<p style="margin:0pt;line-height:115%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name of each exchange on which registered</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:184.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;height:13.35pt">
					<p style="margin:0pt;line-height:115%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Common Stock, $0.01 par value per share</font></p>
				</td>
				<td valign="bottom" style="width:190.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;height:13.35pt">
					<p style="margin:0pt;line-height:115%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">PRPO</font></p>
				</td>
				<td valign="bottom" style="width:184.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;height:13.35pt">
					<p style="margin:0pt;line-height:115%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">The Nasdaq Stock Market LLC</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 23pt 0pt 0pt;line-height:111.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 23pt 0pt 0pt;line-height:111.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 0.35pt;line-height:10.35pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Emerging growth company </font><font style="display:inline;">&#x2610;</font>
		</p>
		<p style="margin:0pt 7.9pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="display:inline;">&#x2610;</font>
		</p>
		<div><hr style="border-width:0;width:100%;height:1.5pt;color:gray;background-color:gray;" align="center"></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;"></table></div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;">
			<tr>
				<td valign="top" style="width:39.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"></font></p>
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">Item 5.02</font></p>
				</td>
				<td valign="top" style="width:464.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">On December 3, 2019, </font><font style="display:inline;color:#000000;">the board of directors (the &#x201C;Board&#x201D;) of Precipio, Inc. (the &#x201C;Company&#x201D;) accepted the resignation of Mr. Samuel D. Riccitelli as Chairman of the Board and Audit Committee, effective </font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">December 1, 2019</font><font style="display:inline;color:#000000;">. &nbsp;Mr. </font><font style="display:inline;font-family:Times New Roman,Times,serif;">Riccitelli</font><font style="display:inline;color:#000000;">&nbsp;resigned in order to focus on recently accepted position as Chief Executive Officer of <a href="#\h"><font style="color:#000000;">Pathnostics</font></a>, a diagnostics company focused on improving antibiotic stewardship through better diagnosis and treatment selection for patients suffering from urinary tract infections. Mr. Riccitelli&nbsp;did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">On December 3, 2019, the Company elected Mr. Richard Sandberg to fill the vacancy left by Mr. Riccitelli&#x2019;s resignation and to serve until the Company&#x2019;s 2020 annual meeting of stockholders or his earlier resignation, retirement or removal.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Mr. Sandberg is a seasoned diagnostics executive with a substantial track record in the field. Mr. Sandberg has served as a director, and, until June of 2019, chairman of Oxford Immunotec Global PLC since 2008.&nbsp;Mr. Sandberg brings a wealth of executive experience to the corporate development and strategic direction of Precipio, having founded Dianon Systems, Inc., a leading anatomic pathology laboratory based in Stratford, CT and having served at various times as &nbsp;Chairman, Chief Executive Officer and Chief Financial Officer.&nbsp; He also served as Chairman and Chief Financial Officer of Lifecodes Corporation, a pioneer in DNA testing technology; Chief Financial Officer and Director of Matritech Inc., a publicly traded biotechnology company specializing in proteomic diagnostic products for the early detection of a variety of cancers; and as Chief Financial Officer of Critical Diagnostics, Inc., a company specializing in developing new diagnostic tests for cardiology. He has also served as a Director of North American Scientific Inc., a publicly held developer and marketer of radiation therapy products and systems for treating breast and prostate cancer, from 2005 to 2009 and as a Director of Ethan Allen Interiors Inc., an international manufacturer and retailer of fine home furnishings, from 2003 to 2009.&nbsp;&nbsp;He continues to serve as chairman, &nbsp;director and/or executive officer of multiple privately-held healthcare companies.&nbsp;&nbsp;Mr. Sandberg earned his bachelor&#x2019;s degree in Business from Northwestern University and his Master of Business Administration from Harvard Business School.&nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Mr. Sandberg will be compensated for his service as a non-employee director under the Company&#x2019;s policy for non-employee director compensation.&nbsp;&nbsp;In connection with the election of Mr. Sandberg and pursuant to the Company&#x2019;s 2017 Stock Option and Incentive Plan, as amended, (the &#x201C;Plan&#x201D;), the Company granted Mr. Sandberg stock options (the &#x201C;Options&#x201D;) to purchase an aggregate of 2,069 and 5,171 shares of the Company&#x2019;s&nbsp;common stock&nbsp;(&#x201C;Common Stock&#x201D;), par value $0.01 per share,&nbsp;respectively, at an exercise price per share equal to the closing price of the Company&#x2019;s Common Stock on the date of grant. The Option to purchase 2,069 shares shall vest equally over twelve months commencing on the date of grant and the Option to purchase 5,171 shares shall vest equally over thirty six months commencing on the date of grant.&nbsp;Mr. Sandberg&nbsp;</font><font style="display:inline;color:#000000;">does not have a family relationship with any of the executive officers or directors of the Company. Mr. Sandberg</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K, and there are no arrangements or understandings between Mr. Sandberg and any other persons pursuant to which Mr. Sandberg was selected as a director of the Company. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">Effective December 3, 2019, the Board appointed Dr. Douglas Fisher as Interim Chairman of the Board and Ms. Kathleen LaPorte&nbsp;as Chairman of the Board&#x2019;s Audit Committee. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Item 8.01 Other Events.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">On December 3, 2019, the Company issued a press release announcing the resignation of Mr. Riccitelli and appointment of Mr. Sandberg the (the &#x201C;Press Release&#x201D;). A copy of the Press Release is attached hereto as Exhibit 99.1 and incorporated herein by reference. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:normal;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">Item 9.01 Financial Statements and Exhibits</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:normal;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(d) Exhibits</font>
		</p>
		<p style="margin:0pt;line-height:normal;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">99.1<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;"><a href="ex-99d1.htm"><font style="font-family:Times New Roman,Times,serif;">Press release dated December 4, 2019</font></a>.&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:12pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">SIGNATURE </font>
		</p>
		<p style="margin:12pt 0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:40.38%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.62%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:46.00%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">PRECIPIO, INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:40.38%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.62%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:46.00%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:40.38%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.62%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.56%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">By:</font></p>
				</td>
				<td valign="top" style="width:39.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">s/ Ilan&nbsp;Danieli&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:40.38%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.62%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.56%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name:</font></p>
				</td>
				<td valign="top" style="width:39.44%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Ilan&nbsp;Danieli</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:40.38%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.62%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.56%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Title:</font></p>
				</td>
				<td valign="top" style="width:39.44%;padding:0pt 2pt 0pt 2pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Chief Executive Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Date:<font style="display:inline;font-family:Times New Roman,Times,serif;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>December 4, 2019 &nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex-99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.4.0.81-->
<!--Created on: 12/4/2019 2:00:49 PM-->
<html>
	<head>
		<title>
			PRPO - 8K - 99.1 Press release Dated Dec 4 2019
		</title>
	</head>
	<body><div style="margin-left:10.4575163398693%;margin-right:10.4575163398693%;"><div style="width:100%">

		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;text-align:right;color:#000000;font-family:Calibri;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.4575163398693%;margin-right:10.4575163398693%;">
		<p style="margin:0pt 0pt 8pt;line-height:107.92%;text-align:center;font-family:Calibri;font-size: 8pt;">
			<a name="_gjdgxs"></a><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:8pt;"><img src="ex-99d1g001.jpg" style="width: 3.825in; height: 0.7453358in" alt="image1.jpg"></font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:107.92%;text-align:center;font-family:Calibri;font-size: 8pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:107.92%;text-align:center;font-family:Calibri;font-size: 14pt;">
			<a name="_30j0zll"></a><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:14pt;">Precipio Announces the Resignation of Samuel Riccitelli and the Introduction of Richard Sandberg to its Board of Directors&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:107.92%;text-align:center;font-family:Calibri;font-size: 12pt;">
			<a name="_1fob9te"></a><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:12pt;">Douglas Fisher, MD will assume the role of interim Chairman of the Board</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:107.92%;text-align:center;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10pt;">NEW HAVEN, CT, (December 4, 2019) &#x2013; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">Specialty diagnostics company </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#1155CC;font-size:10pt;text-decoration:underline;">Precipio, Inc.&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">(</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#1155CC;font-size:10pt;text-decoration:underline;">NASDAQ: PRPO</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">), announced the resignation of Samuel Riccitelli from the board of directors, and his replacement by Richard Sandberg. The transition was ratified at the company&#x2019;s recent board of directors meeting and is effective as of December 1</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;font-size:5pt;top:-4pt;position:relative;line-height:100%">st</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">, 2019.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">Mr. Riccitelli decided to resign so that he can focus on his recently accepted position as the Chief Executive Officer of </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#1155CC;font-size:10pt;text-decoration:underline;">Pathnostics</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">, a diagnostics company focused on improving antibiotic stewardship through better diagnosis and treatment selection for patients suffering from urinary tract infections. &nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">&#x201C;Over the years I have watched Precipio overcome tremendous hurdles on its quest to address the devastating problem of misdiagnosis with their effective suite of products and services which are poised to deliver superior outcomes,'' said Mr. Riccitelli. &#x201C;I am confident that the current board and management team will continue to deliver results that have an outsized impact on the healthcare industry&#x201D;. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">&#x201C;It has been a pleasure to call Sam my colleague, mentor and friend,'' said Ilan Danieli. &#x201C;Although no longer formally on our board, I am confident Sam will remain all of those. Pathnostics is lucky to have him, and I wish him the best of success&#x201D;.&nbsp; </font>
		</p>
		<p style="margin:0pt;line-height:107.92%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:107.92%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10pt;">Richard Sandberg</font>
		</p>
		<p style="margin:0pt;line-height:107.92%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">Joining the board is Richard Sandberg, a seasoned diagnostics executive with a substantial track record in the field. Mr. Sandberg brings a wealth of executive experience to the corporate development and strategic direction of Precipio, having founded Dianon Systems, Inc., a leading anatomic pathology laboratory based in Stratford, CT and having served at various times as Chairman, Chief Executive Officer and Chief Financial Officer.&nbsp; Dianon was acquired by Labcorp for $650M in 2002. Mr. Sandberg has since held a number of positions in the diagnostics products and services industry including Chairman of Oxford Immunotec, Ltd, Chairman of Concile GmbH, Chairman of SuperNova Diagnostics, Inc.,&nbsp;Chairman of Lifecodes Corporation, Director of Poplar Healthcare LLC, Director of Cylex, Inc., and Chief Financial Officer and Director of Matritech, Inc. Mr. Sandberg also serves as Chief Executive Officer of Resolys Bio, Inc, a pharmaceutical company which is developing a pharmaceutical treatment for long-term, chronic traumatic brain injury.&nbsp; </font>
		</p>
		<p style="margin:0pt;line-height:107.92%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:107.92%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">&#x201C;I have always been intrigued with Precipio&#x2019;s disruptive and innovative business model to improve the information available to treating physicians&#x201D;, said Mr. Sandberg. &#x201C;I am excited to be part of a team that encompasses the vision and determination necessary to make a big impact.'' </font>
		</p>
		<p style="margin:0pt;line-height:107.92%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:107.92%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;"> &#x201C;I am delighted to have Richard join our board. Richard has been a friend to the company since its early private days, and there is no better time to have him formally join the board of directors and help chart the path of growth for the company,&#x201D; said Ilan Danieli. &#x201C;Richard brings market, operational, and financial savvy and has led companies from our stage to &gt;$100M in revenues. We are sure to benefit from his expertise.&#x201D;</font>
		</p>
		<p style="margin:0pt;line-height:107.92%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:107.92%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10pt;">Appointment of a new Chairman of the Board </font>
		</p>
		<p style="margin:0pt;line-height:107.92%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 11pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.4575163398693%;margin-right:10.4575163398693%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Calibri;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.4575163398693%;margin-right:10.4575163398693%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.4575163398693%;margin-right:10.4575163398693%;"><div style="width:100%">

		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;text-align:right;color:#000000;font-family:Calibri;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.4575163398693%;margin-right:10.4575163398693%;"><p style="margin:0pt;font-family:Calibri;font-size: 11pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;line-height:107.92%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">The Board of Directors of the Company appointed Dr. Douglas Fisher to act as the Interim Chairman of the Board effective immediately. Dr. Fisher served on the board of the company since 2017. </font>
		</p>
		<p style="margin:0pt;line-height:107.92%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:107.92%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:107.92%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10pt;">About Precipio</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:107.92%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine and Harvard&#x2019;s Dana-Farber Cancer Institute, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#1155CC;font-size:10pt;text-decoration:underline;">www.precipiodx.com</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">. &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:107.92%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10pt;">Forward-Looking Statements</font>
		</p>
		<p style="margin:0pt 0pt 8pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Calibri;font-size: 10pt;">
			<a name="_3znysh7"></a><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">Certain statements in this press release constitute &#x201C;forward-looking statements,&#x201D; within the meaning of federal securities laws, including statements related to ICP technology, including financial projections related thereto and potential market opportunity, plans and prospects and other statements containing the words &#x201C;anticipate,&#x201D; &#x201C;intend,&#x201D; &#x201C;may,&#x201D; &#x201C;plan,&#x201D; &#x201C;predict,&#x201D; &#x201C;will,&#x201D; &#x201C;would,&#x201D; &#x201C;could,&#x201D; &#x201C;should,&#x201D; and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the known risks, uncertainties and other factors described in the Company&#x2019;s definitive proxy statement filed on April 19, 2019 , the Company&#x2019;s Quarterly Report on Form 10-Q for the quarter ended September 3</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">0</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">, 2019 and on the Annual Report on Form 10-K for the year ended December 31, 2018 as well as the Company&#x2019;s prior filings and from time to time in the Company&#x2019;s subsequent filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. All information in this press release is as of the date of the release and the Company does not undertake any duty to update this information, including any forward-looking statements, unless required by law.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:107.92%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10pt;">Inquiries:</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:107.92%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#1155CC;font-size:10pt;text-decoration:underline;">investors@precipiodx.com</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:justify;text-justify:inter-ideograph;color:#222222;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10pt;">+1-203-787-7888 Extension 523</font>
		</p></div><div style="margin-left:10.4575163398693%;margin-right:10.4575163398693%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Calibri;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.4575163398693%;margin-right:10.4575163398693%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex-99d1g001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d1g001.jpg
M_]C_X  02D9)1@ ! @$       #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "D TH# 2(  A$! Q$!_\0
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MZUG-4TO=8*_4[$5A>(_$^G^%=/2[U R$.^Q(XERSGV'%;M>4_&W_ )!VD_\
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M%F]I>1AXVZ'NI]0>QK:G6<='L<U7#QGJMSP.NR\%^+6TN=-.O9,V4APC,?\
M5'_XFL+7M"N=!U!K:;YHV^:*4#AU_H:RJZVE4B<$7*E(^BP01D4M<'\/_$9O
MK;^RKI\SVZYB8GEH_3ZC^5=Y7!*+B[,]6$U.-T+1114EA1110 4444 %%%%
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M^U>M>&O$]OKMOM.([M!^\BS^H]17?0Q"GI+<]7"XI5%RRW.CHHHKJ.X****
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M?!^D^*+;49-269C Z!/+DV]0<_RK>G"')S2(;=[(W_\ A=T'_0"D_P# D?\
MQ-'_  NZ#_H!2?\ @2/_ (FMW_A47A?_ )YW?_?\T?\ "HO"_P#SSN_^_P":
M+T>P>\87_"[H/^@%)_X$C_XFD_X7A!_T I/_  )'_P 36]_PJ+PO_P \[O\
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M_#KQ,OB+P[&DKYOK,"*8'JP_A?\ $#\P:[,5E).+LQH6BBBD,**** "BBB@
MHHHH 2O*OC;_ ,@W2?\ KM)_(5ZK7E7QM_Y!ND_]=I/Y"KI?&A2V-;X/?\B0
MW_7W)_):[^N ^#W_ ")#?]?<G\EKOZ4_C8+8\#^,'_([_P#;K'_-J]A\'?\
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M%:4OC0I;&M\'O^1(;_K[D_DM=_7 ?![_ )$IO^ON3^2UW]34^-@MCP3XP_\
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M]UUYCF7^1'^>*WTK+S(UB?2]+7G'AKXK:5JJI!JI&GW70LQ_=-]&_A_'\Z]
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M[VW_ 'X%)_PMKQ7_ ,_%M_WX%>X_\(_HO_0(L/\ P&3_  H_X1_1?^@18?\
M@,G^%/VD/Y0L^YX?_P +;\5_\][;_OP*/^%M^*_^>]M_WX%>X?\ "/Z+_P!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#SWXD>"CX@T_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBQ.4!_WL8K%\3:) WB;2XH6:"#5',=Y%&=JRA,,,X[]1FNVCM+>*V%M'!&L
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M],TR7SII1]V68?=5?7'6K</_ "4NY_[!:?\ HPU6RLR0_M7Q7_T+4'_@<O\
MA5623Q-K<4EEY%GIL1^2>5;CSI%'< #H<'O78UR5_GP]XJBU$<:?J1$%UZ)*
M/N/^/0T1=]D#1H7UC!IO@Z\LK8;88;*15]?N'D_SK/TZ[UBW\-:,-,TR*[0V
M<>]GN!'M.T<8Q6WKW_(NZG_UZ2_^@&H_#'_(KZ5_UZ1_^@BA/W;ON'4S_P"U
M/%?_ $+MM_X'#_"MVSDN)+2)[J%89V7+QJ^X*?3/>K-%2W?H,6BBB@84444
M%%%% !1110 4444 %%%% !1110 QE5CM901Z$4U55?NHH^@HHH DI:** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M.U9VHZ99ZM;"UO85EB9<X/4'U!Z@T44+<3/-_$.H:IX3N3:Z=JUVT(/RK<%9
M-H]!E>E8O_">^)O^@F?^_,?_ ,31172DK&1Z'K[-?^ H))R2T_V9I".,DNF:
MZY/NCZ445A+8T6XZBBBI*.9T9%3QAXDV]&-N2.V?+IWA% D6L8S_ ,A2?K]1
M116DMG\B4=)111691S'CB(2>&G(9D:.9&5EQD$'CK7'_ -L:U_T&;O\ */\
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7XG?2;)GN9V9H$)8OR3M%%%8QV-&?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
